Global Expansion of Genetic Screening as Demand for Personalized Medicine Rises
Global, Thursday, 24 April 2025.
The genetic testing market is set to grow from $11.4 billion in 2023 to $18.9 billion by 2028, driven by advances in genomics and the rise of personalized healthcare.
Market Growth and Innovation
The genetic screening testing market is experiencing unprecedented expansion, driven by technological advancements in genetic testing and increased consumer interest in personalized medicine. Key industry players, including Exact Science, Labcorp Genetics Inc., and Blueprint Genetics, are at the forefront of this transformation [1]. The market’s growth is particularly evident in North America, which currently holds the largest market share, followed by Europe and the Asia-Pacific region [1].
Breakthrough in Newborn Screening
A significant advancement in genetic screening is demonstrated by the GUARDIAN study, which has successfully screened approximately 10,000 infants for over 450 treatable genetic conditions as of April 2025. The study has shown remarkable results, with 120 positive tests for genetic conditions, of which 110 cases were not identified through conventional screening methods [2]. This represents a substantial improvement over traditional newborn screening, which typically only tests for 30 to 80 genetic conditions [2].
Global Access and Implementation
Recent developments in Asia highlight the expanding reach of genetic testing services. Gene Solutions has established a significant presence across eight Asian countries, reaching over 4,500 hospitals and clinics [5]. This expansion is complemented by strategic collaborations, such as the partnership between Gene Solutions and Element Biosciences, which aims to enhance access to genetic testing through advanced sequencing platforms [5].
Cancer Genomics and Precision Medicine
The genomic cancer panel and profiling market is showing robust growth, with a projected CAGR of 9.67% from 2025 to 2035 [6]. This growth is supported by approximately 19.97 million cancer cases reported in 2022, driving increased demand for genomic profiling in early diagnosis, prognosis, and therapy selection [6]. Major companies like Burning Rock Dx, Caris Life Sciences, and Illumina are leading innovations in this sector, particularly in solid tissue testing and multi-gene panel development [6].